Skip to main content
SpringerLink
Log in

„Targeted therapy“ des metastasierten Mammakarzinoms

Targeted therapy in metastatic breast cancer

  • Leitthema
  • Published:
Der Gynäkologe Aims and scope

Zusammenfassung

Das metastasierte Mammakarzinom ist trotz verschiedener zur Verfügung stehender Therapieoptionen eine leider nicht zu kurierende Erkrankung. Neben antiendokrinen, chemo- wie auch strahlentherapeutischen Möglichkeiten sind in den letzten Jahren zielgerichtete Therapiekonzepte kontinuierlich in den Vordergrund gerückt. Die Behandlung in der metastasierten Situation ist individuell und unter Berücksichtigung der Lebensqualität der Patientinnen zu entscheiden. Kombinierte Chemotherapien sind effektiv, bezüglich ihrer Toxizität allerdings nicht zu unterschätzen. Daher sind Monotherapien die bevorzugte Therapieform. Durch den Einsatz neuer, zielgerichteter Substanzen, die in Kombination mit antiendokriner oder Chemotherapie appliziert werden können, lassen sich effektive Kombinationstherapien mit meist tolerablen Toxizitäten durchführen. Jüngst publizierte Daten zeigen sogar Synergismen einiger neuer Substanzen, die Mut machen, zukünftig auch chemotherapiefreie Regime in der metastasierten Situation einzusetzen.

Abstract

Metastatic breast cancer is incurable in most cases despite a variety of therapeutic approaches. Although antiendocrine, chemotherapeutic, and radiotherapeutic options exist, targeted therapies against cancer have come increasingly to the fore in recent years. Treatment has to be individualized, and quality of life must influence the treatment plan. Combined chemotherapies are effective, but their toxicity dare not be underestimated. Thus monotherapy is the preferred form of treatment. The use of new compounds that are applied in combination with antiendocrine or chemotherapy leads to highly effective treatment options with generally well tolerated toxicity. Recently published data even showed encouraging synergistic effects of several new substances, which could result in future metastatic treatment without chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Andre F, Campone M, Hurvitz S, Vittori L et al (2008) Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. J Clin Oncol 26(15S):41s Abstract 1003

    Article  Google Scholar 

  2. Awada A, Cardoso F, Fontaine C, Dirix L et al (2007) The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 44:84–91

    Article  PubMed  Google Scholar 

  3. Baselga J, Cameron D, Miles D, Verma S et al (2007) Objective response rate in a phase II multi center trial of pertuzumab, a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab in patients with HER2-positive metastatic breast cancer which has progressed during treatment with trastuzumab. J Clin Oncol 25(18S):33s Abstract 1004

    Article  Google Scholar 

  4. Beeram M, Burris H, Modi S, Birkner M et al (2008) A phase I study of trastuzumab-DM-1, a first in class HER2 antibody-drug conjugate, in patients with advanced HER2+ breast cancer. J Clin Oncol 26(15S):48s Abstract 1028

    Google Scholar 

  5. Cameron D, Casey M, Press M, Lindquist D et al (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: update efficacy and biomarker analyses. Breast Res Treat 112:533–543

    Article  CAS  Google Scholar 

  6. Ciardiello F, Troiani T, Caputo F et al (2006) Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Brit J Cancer 94:1604–1609

    PubMed  CAS  Google Scholar 

  7. Cortes L, Mayer E, Marcom P et al (2005) Open label, randomized, phase II study of pertuzumab in patients with metastatic breast cancer with low expression of HER2. J Clin Oncol 23(suppl 16):3068

    Article  Google Scholar 

  8. Cristofanilli M, Valero V, Mangalik A, Rabinowitz I et al (2008) A phase II multicenter, double blind, randomized trial to compare anastrozole plus gefitinib with anastrazole plus placebo in postmenopausal women with hormone receptor positive metastatic breast cancer. J Clin Oncol 26(15S):44s Abstract 1012

    Article  Google Scholar 

  9. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z et al (2008) Phase III, double.blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26(34):5544–5552

    Article  Google Scholar 

  10. Extra JM, Antoine EC, Vincent-Salomon A, Bergougnoux L et al (2006) Favourable effect of continued trastuzumab treatment in metastatic breast cancer patients: results from the French Hermine cohort study. Breast Cancer Res Treat 100(suppl 1):S102 Abstract 2064

    Google Scholar 

  11. Gelmon K, Furnoleau P, Verma S, Wardley A et al (2008) Results of a phase II trial of trastuzumab and pertuzumab in patients with HER2 positive metastatic breast cancer who had progressed during trastuzumab therapy. J Clin Oncol 26(15S):47s Abstract 1026

    Google Scholar 

  12. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743

    Article  PubMed  CAS  Google Scholar 

  13. Holden S, Beeram M, Krop I, Burris H et al (n d) A phase I study of weekly dosing of trastuzumab-DM1 in patients with advanced HER2+ breast cancer. J Clin Oncol 26(15S):48s Abstract 1029

    Google Scholar 

  14. Lin NU, Dieras V, Paul D, Lossignol D et al (2007) EGF105084, a phase II study of lapatinib for brain metastases in patients with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). J Clin Oncol 25(18S):35S Abstract 1012

    Google Scholar 

  15. Mackey JR, Kaufman B, Clemens M, Bapsy PP et al (2006) Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat 100(suppl 1):5S Abstract 3

    Google Scholar 

  16. Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23:4265–4274

    Article  PubMed  CAS  Google Scholar 

  17. Miles D, Chan A, Romieu G, Dirix L et al (2008) Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 26(15S):43s Abstract LBA1011

    Google Scholar 

  18. Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792–799

    Article  PubMed  CAS  Google Scholar 

  19. Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676

    Article  PubMed  CAS  Google Scholar 

  20. National Institute of Health (2008) http://www.clinicaltrials.gov/ct/show/

  21. O’Shaugnessy J, Blackwell KL, Burstein H, Storniolo AM et al (2008) A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 26(15S):45s Abstract 1015

    Google Scholar 

  22. Pegram M, Forbes J, Pienkowski T et al (2007) BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). J Clin Oncol 25(18S):968S Abstract LBA1008

    Google Scholar 

  23. Perez EA, Suman VJ, Rowland KM et al (2005) Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 6:425–432

    Article  PubMed  CAS  Google Scholar 

  24. Robert N, Leyland-Jones B, Asmar L et al (2006) Randomized phase III study of trastuzumab, paclitaxel and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24:2786–2792

    Article  PubMed  CAS  Google Scholar 

  25. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    Article  PubMed  CAS  Google Scholar 

  26. Slamon D, Yeon CH, Pienkowski T et al (2004) Survival analysis from two open-label non-randomized phase II trials of trastuzumab (H) combined with docotaxel (T) and platinums (C, cisplatin or carboplatin) (TCH) in women with HER2+ advanced breast cancer (ABC). J Clin Oncol 22(14S) Abstract 642

    Google Scholar 

  27. Slamon D, Gomez HL, Kabbinavar FF, Amit O et al (2008) Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. J Clin Oncol 26(15S):45s Abstract 1016

    Google Scholar 

  28. Minckwitz G von, Zielinski C, Maarteense E, Vogel M et al (2008) Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05). J Clin Oncol 26(15S):47s abstract 1025

    Google Scholar 

  29. Yang SX, Simon RM, Tan AR et al (2005) Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer. Clin Cancer Res 11:6226–6232

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Deutschland

    M. Thill, C. Dittmer, K. Röder, K. Diedrich & D. Fischer

Authors
  1. M. Thill
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Dittmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Röder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Diedrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Thill.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thill, M., Dittmer, C., Röder, K. et al. „Targeted therapy“ des metastasierten Mammakarzinoms. Gynäkologe 42, 170–178 (2009). https://doi.org/10.1007/s00129-008-2296-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00129-008-2296-4

Schlüsselwörter

Keywords

Search

Navigation